Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutimlimab in Chronic Immune Thrombocytopenia
NCT03275454Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2017
- Primary completion
- Feb 2021
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of sutimlimab in immune thrombocytopenia (ITP), sponsored by Sanofi. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 97 weeks, Number of Participants With Premature Study Terminations at 97 weeks and 1 more. Started Aug 2017; status: completed.
02
Drugs
sutimlimab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03275454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275454.